Eton Acquires Rare Disease Product Candidate ET-600 From Tulex Pharmaceuticals For Undisclosed Sum; Potential For NDA Submission In Q2 2024
ET-600 is an innovative product candidate under development for the treatment of an endocrinology condition that is estimated to impact less than 5,000 pediatric patients in the U.S. If approved, ET-600 is expected